by Damon Race | May 16, 2025 | In the News
When Damon Race, a Raleigh-based biopharmaceutical entrepreneur and investor, wanted to start a new company, he didn’t have to go far to find the founding technologies. After looking at “30 to 40 assets” nationally, in October of 2020, Race chose to in-license a gene...
by Damon Race | Apr 8, 2025 | In the News
Gene therapy developed at Duke to be commercialized by a local biotechnology company by Fedor Kossakovski Duke University recently signed an exclusive license with GeneVentiv Therapeutics, a Raleigh-based gene therapy company, to commercialize a gene therapy developed...
by Damon Race | Apr 16, 2024 | In the News
Damon R. Race, President & CEO RALEIGH, N.C., April 16, 2024 /PRNewswire/ — GeneVentiv Therapeutics, developer of GENV-HEM (AAV8.FVa) for all hemophilias, announced today it has been awarded a Direct to Phase II Small Business Innovation Research (SBIR)...
by Damon Race | Mar 26, 2024 | In the News
ReciBioPharm, GeneVentiv to advance GENV-HEM to Phase 1/2 clinical testing by Margarida Maia, PhD | March 15, 2024 ReciBioPharm and GeneVentiv Therapeutics are teaming up to advance the development of GENV-HEM, a gene therapy for all hemophilia patients, including...
by Damon Race | Aug 29, 2023 | In the News
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Damon Race, CEO of GeneVentiv Therapeutics. The North Carolina-based startup hopes to develop a universal gene therapy that will benefit patients with hemophilia A or B with or without...
by Damon Race | Sep 12, 2022 | In the News
By Zac Ezzone – Staff writer, Triangle Business Journal Sep 1, 2022 A UNC-Chapel Hill spinout developing gene therapies focused on rare blood diseases and disorders has raised $1.4 million to support its efforts. The company, GeneVentiv Therapeutics, raised the...
Recent Comments